A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Protocol Number: CA224069

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- up to 30 years old - pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT) - participants with pathologically confirmed R/R NHL after failure or non-response to second line therapy, including but not limited to primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL)

Exclusion Criteria:

- aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic lymphoma, and NK/T-cell lymphoma/leukemia - prior autologous stem cell transplantation (HDCT/ASCT) - see link to clinicaltrials.gov for additional exclusion criteria

Conditions & Interventions

Interventions:
Drug: Nivolumab, Drug: Relatlimab
Conditions:
Cancer
Keywords:
Hodgkin Disease, Lymphoma, Non-Hodgkin

More Information

Description: CA224069 is an open-label, Phase 1/2 clinical trial of relatlimab + nivolumab in children, adolescents and young adults with Recurrent or Refractory Classical Hodgkin Lymphoma (R/R cHL) and Non-Hodgkin Lymphoma (NHL). Part A will encompass safety and dose determination of relatlimab + nivolumab. Part B will be composed of an expansion cohort of cHL (Cohort 1) and an exploratory assessment in NHL (Cohort 2).
Study Contact: Allison Fullenkamp - fulle631@umn.edu
Principal Investigator: Peter Gordon
IRB Number: SITE00001545